A Survey for Changed Control Policies of Hepatitis B in Republic of Korea

Han, Ji Yoon; Jung, Tae Woong; Koh, Dae Kyun; Kim, Jong Hyun

doi:10.14776/kjpid.2011.18.2.124

Cited by 6 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hepatitis B vaccination was introduced into the Republic of Korea (hereafter Korea) beginning in 1983, and a national mandatory immunization program for infants has been conducted since 1995. In addition, in order to prevent vertical infection, costs for a prevention program including hepatitis B vaccination and immunoglobulin of infants born to hepatitis B-infected mothers have been supported since July 2002 [ 4 ]. As a result of these various efforts, HBsAg seropositivity in the Korea are reported to decrease continuously [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Changing Hepatitis B surface antigen seroprevalence and epidemiologic characteristics in the Republic of Korea, 1998-2013

Lee

Cho

et al. 2015

Epidemiol Health

View full text Add to dashboard Cite

OBJECTIVES:This study investigated changes in hepatitis B seroprevalence from 1998 to 2013, and to identify differences in epidemiologic characteristics between hepatitis B surface antigen (HBsAg)-positive and HBsAg-negative people.METHODS:HBsAg seropositive rates were compared by year, sex, and age using the blood test data from the periods I to VI (1998-2013) of the Korea National Health and Nutrition Examination Survey. Interviews and self-administered surveys were conducted to collect data on health behavior, quality of life, comorbidities, and health care utilization.RESULTS:HBsAg seropositive rates in the Republic of Korea decreased from 4.6% in 1998 to 2.9% in 2008, and then remained the same for the next five years. While seropositive rates by age were the highest at 35 to 39 years of age in 1998, it peaked at 50 to 54 years of age in 2013. HBsAg-positive people showed high values from two liver function tests, including glutamic-oxaloacetic transaminase and glutamic-pyruvic transaminase, and the prevalence rates of liver cirrhosis and liver cancer were also significantly high. Indices for health behavior and quality of life showed no significant differences between HBsAg-positive and HBsAg-negative people.CONCLUSIONS:While HBsAg seropositive rates tended to decline after 1998, there have been no significant changes over the most recent five years. We should focus on treatment of existing hepatitis B patients along with immunization programmes to prevent new hepatitis B infections. In addition, it may be necessary to encourage HBsAg-positive people to follow healthier life-styles in order to prevent further progression of hepatitis B to liver cirrhosis and liver cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Changing Hepatitis B surface antigen seroprevalence and epidemiologic characteristics in the Republic of Korea, 1998-2013

Lee

Cho

et al. 2015

Epidemiol Health

View full text Add to dashboard Cite

show abstract

“…While the recombinant HBV vaccine has been assumed to have comparable efficacy with plasma-derived vaccine (But et al, 2008, Gerety andEllis, 1987), several studies reported a higher rate of the disappearance of anti-HBs with recombinant DNA vaccine than with plasma-derived one (Kim et al, 2017, Yuen et al, 2004. Because the plasma-derived vaccine was gradually replaced by recombinant vaccine until 1996 (Han et al, 2011), there is still possibility of use of plasma-derived vaccine among our youngest generation. Although we do not have the information of the type of HBV vaccine used in the population, the low anti-HBs seropositivity in the youngest women can be due to more dominant use of recombinant J o u r n a l P r e -p r o o f HBV vaccine in recent generations (Bialek et al, 2008, Kim et al, 2017.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis B surface antigen and antibody positivity among women of childbearing age after three decades of universal vaccination in South Korea

Hur

Choe

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

“…B형 간염 바이러스(hepatitis B virus [HBV])에 의한 만성 감염자는 약 25-30%에서 만성 간염, 간경화, 간세포암종 등의 만성 간질환으로 조기에 사망하는데, 전 세계적으로 약 2억 4천만 명이 만성 감염자이며 HBV 감염과 관련된 사망은 약 65만명으로 추산된다. 1,2) 우리나라는 B형 간염 백신과 1회용 주사기를 사용하기 이전인 1970년대 말부터 1980년대 초에는 전 인구와 초등•중학교 학생에서의 HBsAg 양성률이 각각 6.6-8.6%, 3) 4.8% 4) 이었던 것에 비해, B형 간염 백신을 1982년부터 매우 일찍 도입하고 높은 접종률을 유지함과 동시에 1회용 주사기 사용을 법제화한 이후로 급격히 감소하여 5) 2014년의 조사에 의하면 10세 이상 전 인구와 10-18세 연령에서 각각 2.9%, 0.1%로 매우 낮아졌다. 6) 그러나 산모 연령층의 HBsAg 양성률이 아직 2-3%(19-29세 1.7%, 30-39세 3.2%)이고, 6) 이들의 HBeAg 양성률이 30-40% 7) 이므로 주산기 감염 예방조치에 실패하여 HBV 만성 감염자로 되는 소아가 매년 약 300-400명씩 생기게 된다.…”

Section: 서론unclassified

Therapeutic Efficacy of Lamivudine in Children and Adolescents with Chronic Hepatitis B

Choi

Bae

Kim

et al. 2018

Pediatr Infect Vaccine

Self Cite

View full text Add to dashboard Cite

Purpose: This prospective study aimed to investigate the therapeutic efficacy of lamivudine in children with chronic hepatitis B virus (HBV) infection. Methods: During July 2003 through October 2015, children with chronic hepatitis B who visited our institution were included in this study. Fifty-five patients, who received first-line treatment of lamivudine (3 mg/kg, 100 mg maximum) for over three months, were enrolled. After initiating lamivudine, alanine aminotransferase (ALT), HBV-DNA, and HBV markers were followed up at 1 month, 3 months, and every 3 months, thereafter. The treatment endpoint was determined as 1) normalization of ALT, 2) HBeAg seroconversion, and 3) anti-HBe positivity for twelve consecutive months. Results: Thirty-one male (56.4%) and 24 female (43.6%) patients were included. The mean age at treatment initiation was 8.1 years. The mean duration of treatment was 23.4 months. ALT normalization was found in 98.2% (54 of 55). Anti-HBe seroconversion was found in 70.6% (36/51). Loss of HBsAg was found in 10.9% (6/55). All biochemical responses occurred under age seven. The rate of virologic response (defined as HBV-DNA <2,000 IU/mL) at six months after treatment initiation was 78.7% (37/47). At twelve months after reaching treatment endpoint, 87.2% (34/39) maintained their virologic response. Resistance to lamivudine was found in 16.4% (9/55). Conclusions: Lamivudine treatment in Korean pediatric patients with chronic hepatitis B showed better outcomes compared with other studies that implemented similar protocols in foreign populations. Further studies are needed to investigate the efficacy of newly recommended antiviral drugs on the Korean pediatric population.

show abstract

A Survey for Changed Control Policies of Hepatitis B in Republic of Korea

Cited by 6 publications

References 7 publications

Changing Hepatitis B surface antigen seroprevalence and epidemiologic characteristics in the Republic of Korea, 1998-2013

Changing Hepatitis B surface antigen seroprevalence and epidemiologic characteristics in the Republic of Korea, 1998-2013

Hepatitis B surface antigen and antibody positivity among women of childbearing age after three decades of universal vaccination in South Korea

Therapeutic Efficacy of Lamivudine in Children and Adolescents with Chronic Hepatitis B

Contact Info

Product

Resources

About